The Coombs Titre test is primarily designed to detect antibodies against the Rh factor on the surface of red blood cells, aiding in the diagnosis of Rh incompatibility and autoimmune haemolytic anaemias/

By monitoring antibody levels in Rh-negative mothers carrying Rh-positive foetuses, the Coombs Titre helps healthcare providers implement timely interventions, such as Rh immunoglobulin administration, to prevent or manage HDN.

The Coombs Titre is crucial in obstetrics to assess Rh compatibility during pregnancy and in the diagnosis and management of autoimmune haemolytic anaemias, providing targeted insights for tailored treatment plans.

While the Coombs Titre specifically targets antibodies against the Rh factor, other blood type incompatibilities are typically assessed through different blood typing and crossmatching procedures.

The Coombs Titre involves collecting a blood sample, treating it with Coombs reagent, and then examining for agglutination or clumping under a microscope to determine the presence of antibodies.

The Coombs Titre is often included in routine prenatal screening, especially when there is Rh incompatibility between the mother and foetus, to monitor antibody levels and ensure appropriate management.

Yes, the Coombs Titre results can change as the pregnancy progresses, making regular monitoring essential for adapting interventions and ensuring the health of both the mother and the foetus.

The Coombs Titre is a generally safe procedure with minimal risks, such as slight discomfort or bruising at the site of blood collection, but serious complications are rare.

The Coombs Titre is not typically used to assess compatibility for blood transfusions; instead, it is more focused on detecting antibodies related to Rh compatibility and autoimmune haemolytic anaemias.

While the Coombs Titre is a valuable tool in diagnosing autoimmune haemolytic anaemias, additional tests and clinical assessments are often required to differentiate between various subtypes of this condition.